Lumida
/RCUS
⌘K
Arcus Biosciences Inc

Arcus Biosciences Inc

RCUS
$27.37USD↑+2.74%+0.73 today

MARKET CAP

3.4B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$26 – $28

52W RANGE

$9
$32

AI Summary

Stalk
StalkMedium

In Stage 2 Advancing, RCUS maintains higher highs and higher lows above its rising 50-day SMA, reflecting a bullish medium-term bias within a long-term uptrend. However, a Bearish Pivot Point and failure to reclaim the 9- and 20-day EMAs have turned short-term momentum negative. Execution should be deferred until price shows constructive pullback absorption at the 50-day SMA or a clear reclaim of the short-term EMAs.

  • ↑Casdatafan achieves 45% ORR vs Belzutifan’s 22.5% and 15.1-month median PFS
  • ↑Cash reserves of ~$1B at Q2 2024 fund operations into mid-2027
  • ↓Negative profitability and earnings yield reflect weak return generation
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Arcus Biosciences, Inc. (NASDAQ: RCUS) is a clinical-stage biotechnology firm focused on developing innovative therapies for cancer treatment, particularly utilizing their lead candidate, Casdatafan, a HIF-2-alpha inhibitor. The company is targeting renal cell carcinoma (RCC), a significant area of unmet medical need, and possesses a robust portfolio extending into immunology. This strategic position places Arcus in the growing oncology sector, with potential to redefine treatment modalities against established therapies.

Bull says

  • ↑Casdatafan achieves 45% ORR vs Belzutifan’s 22.5% and 15.1-month median PFS
  • ↑Cash reserves of ~$1B at Q2 2024 fund operations into mid-2027
  • ↑Truist initiates coverage with Buy rating and $35 price target
  • ↑High momentum and strong institutional ownership signal market confidence
  • ↑Peak RCC opportunity exceeds $5 billion for Casdatafan adoption
  • ↑Rapid Phase III enrollment expected to complete by year-end 2026

Bear says

  • ↓Negative profitability and earnings yield reflect weak return generation
  • ↓Declining growth and revision metrics signal revenue and EPS headwinds
  • ↓High leverage exposure and small size increase capital-structure risks
  • ↓Key Phase III results for PEAK 1 by end-2026 create execution risk
  • ↓Projected cash drop to $600 m by end-2026 may strain funding runway
  • ↓Regulatory and competitive pressures could delay approval or limit share

Investment themes with RCUS

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-09-2026neutral

Transcript signals

Bull points

  • Sales for RCC drugs in just the major markets are anticipated to grow to $13 billion by 2030.
  • We have a clear path to consolidate the market and entrench Casdatafan as the primary backbone therapy.
  • We believe our commercial opportunity here exceeds $2 billion.

Bear points

  • We expect to end 2026 with approximately $600 million in cash, indicative of the declining spend we expect over the year.
  • For example, as our late-stage efforts have become focused on CAS DataFan, we have decreased our headcount by approximately 10%.
  • Our R&D expenses for the first quarter are stated net of reimbursements and were $122 million and included non-recurring workforce costs.
Read full transcript analysis ›